United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Technology Industry News BT Group H1 FY26 results: Fibre acceleration, mobile gains, and cost transformation steady the ship BT Group reported flat EBITDA and a 3% revenue decline in H1 FY26, with fibre growth and cost savings helping offset legacy declines. bySrinathNovember 7, 2025